MY143576A - Chiral derivatives of 3-phenyl-propionic acid, particularly useful for the treatment of diseases associated with ppar-alpha or ppar-gamma - Google Patents
Chiral derivatives of 3-phenyl-propionic acid, particularly useful for the treatment of diseases associated with ppar-alpha or ppar-gammaInfo
- Publication number
- MY143576A MY143576A MYPI20033798A MYPI20033798A MY143576A MY 143576 A MY143576 A MY 143576A MY PI20033798 A MYPI20033798 A MY PI20033798A MY PI20033798 A MYPI20033798 A MY PI20033798A MY 143576 A MY143576 A MY 143576A
- Authority
- MY
- Malaysia
- Prior art keywords
- alkoxy
- ppar
- alkyl
- fluoro
- hydrogen
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical class OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 title 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 102000023984 PPAR alpha Human genes 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 abstract 2
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 230000003143 atherosclerotic effect Effects 0.000 abstract 1
- 230000036772 blood pressure Effects 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical class [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Substances N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
THE PRESENT INVENTION IS CONCERNED WITH COMPOUNDS OF FORMULA (I) H WHEREIN R1 IS ARYL OR HETEROARYL; R2 IS HYDROGEN, LOWER-ALKYL, OR FLUORO-LOWER-ALKYL; R3 AND R4 INDEPENDENTLY FROM EACH OTHER ARE HYDROGEN, HYDROXYL, HALOGEN, LOWER-ALKYL, FLUOROLOWER-ALKYL, HYDROXYL-LOWER-ALKYL, LOWER-ALKOXY-LOWER-ALKYL, LOWER-ALKOXY, FLUOROLOWER-ALKOXY, HYDROXYL-LOWER-ALKOXY, LOWER-ALKOXY-LOWER-ALKOXY, OR LOWER-ALKENYL, WHEREIN AT LEAST ONE OF R3 AND R4 IS NOT HYDROGEN; R5 IS LOWER-ALKOXY, FLUORO-LOWER-ALKOXY, LOWER-ALKENYLOXY, FLUORO-LOWER-ALKENYLOXY, ARYLOXY, ARL-LOWER-ALKOXY, OR ARYL-FLUORO-LOWER-ALKOXY; R6 IS HYDROGEN OR LOWER-ALKYL; N IS 1; AND PHARMACEUTICALLY ACCEPTABLE SALTS AND/OR PHARMACEUTICALLY ACCEPTABLE ESTERS THEREOF. THE COMPOUNDS OF THE PRESENT INVENTION INHIBIT PPARα AND PPAR SIMULTANEOUSLY. THEY ARE USEFUL FOR THE TREATMENT AND/OR PREVENTION OF DISEASES WHICH ARE ASSOCIATED WITH PPARα AND/OR PPAR, AS, FOR EXAMPLE, DIABETES, AND PARTICULARLY NON-INSULIN DEPEND DIABETES MELLITUS, ELEVATED BLOOD PRESSURE, INCREASED LIPID AND CHOLESTEROL LEVELS, ATHEROSCLEROTIC DISEASES AND METABOLIC SYNDROME.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02022286 | 2002-10-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY143576A true MY143576A (en) | 2011-05-31 |
Family
ID=32049977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI20033798A MY143576A (en) | 2002-10-07 | 2003-10-06 | Chiral derivatives of 3-phenyl-propionic acid, particularly useful for the treatment of diseases associated with ppar-alpha or ppar-gamma |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US6969725B2 (en) |
| EP (1) | EP1551814B1 (en) |
| JP (1) | JP4414886B2 (en) |
| KR (1) | KR100623819B1 (en) |
| CN (1) | CN100415727C (en) |
| AR (1) | AR041481A1 (en) |
| AT (1) | ATE402153T1 (en) |
| AU (1) | AU2003273949B2 (en) |
| BR (1) | BR0315114A (en) |
| CA (1) | CA2499721C (en) |
| CO (1) | CO5540385A2 (en) |
| DE (1) | DE60322408D1 (en) |
| DK (1) | DK1551814T3 (en) |
| ES (1) | ES2311110T3 (en) |
| GT (1) | GT200300218A (en) |
| HR (1) | HRP20050308A2 (en) |
| IL (1) | IL167250A (en) |
| MX (1) | MXPA05003392A (en) |
| MY (1) | MY143576A (en) |
| NO (1) | NO330171B1 (en) |
| NZ (1) | NZ538465A (en) |
| PA (1) | PA8584501A1 (en) |
| PE (1) | PE20040591A1 (en) |
| PL (1) | PL208743B1 (en) |
| PT (1) | PT1551814E (en) |
| RU (1) | RU2303593C2 (en) |
| SI (1) | SI1551814T1 (en) |
| TW (1) | TWI343915B (en) |
| UY (1) | UY28006A1 (en) |
| WO (1) | WO2004031162A1 (en) |
| ZA (1) | ZA200502664B (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7105551B2 (en) * | 2000-12-20 | 2006-09-12 | Smithkline Beecham Corporation | Thiazole derivatives for treating PPAR related disorders |
| AR041481A1 (en) * | 2002-10-07 | 2005-05-18 | Hoffmann La Roche | ARILPROPIONIC-OXAZOL ACID DERIVATIVES AND ITS USE AS PPAR AGONISTS |
| JP2006514976A (en) * | 2002-11-15 | 2006-05-18 | カディラ ヘルスケア リミティド | Substituted aralkyl derivatives |
| US7262303B2 (en) * | 2003-09-29 | 2007-08-28 | Hoffman-La Roche Inc. | Process for the production of chiral propionic acid derivatives |
| US20100063041A1 (en) * | 2007-03-07 | 2010-03-11 | Ho-Sang Moon | Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators, method of the same, and pharmaceutical composition comprising the same |
| RU2361581C2 (en) | 2007-09-14 | 2009-07-20 | Закрытое Акционерное Общество "Мастерклон" | Pharmaceutical composition possessing antidiabetic, hypolipidemic, hypoglycemic and cholesterol lowering action, way of its reception and ways of treatment of specified diseases |
| EA022417B1 (en) * | 2008-10-21 | 2015-12-30 | Саймабэй Терапевтикс, Инк. | Aryl gpr120 receptor agonists and uses thereof |
| AR074760A1 (en) | 2008-12-18 | 2011-02-09 | Metabolex Inc | GPR120 RECEIVER AGONISTS AND USES OF THE SAME IN MEDICINES FOR THE TREATMENT OF DIABETES AND METABOLIC SYNDROME. |
| CN101805336B (en) * | 2009-02-13 | 2012-05-30 | 天津药物研究院 | Compound containing tryptophan and isoxazole skeleton, preparation method and application thereof |
| CN101805337B (en) * | 2009-02-13 | 2012-05-23 | 天津药物研究院 | Compound containing proline and isoxazole skeleton, preparation method and application thereof |
| US8637096B2 (en) | 2009-12-04 | 2014-01-28 | Curtis C. Stojan | Compositions and method for enhancing insulin activity |
| US8299117B2 (en) | 2010-06-16 | 2012-10-30 | Metabolex Inc. | GPR120 receptor agonists and uses thereof |
| CN102285933B (en) * | 2010-06-18 | 2016-03-09 | 浙江海正药业股份有限公司 | A kind of have the compound of agonism, its preparation method and application to hypotype peroxisome proliferator-activated receptor |
| EP2758041B1 (en) | 2011-09-20 | 2021-01-13 | Basf Se | Low-molecular modulators of the cold-menthol receptor trpm8 and use of same |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5089514A (en) * | 1990-06-14 | 1992-02-18 | Pfizer Inc. | 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents |
| GB9604242D0 (en) * | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
| RU2174121C2 (en) * | 1996-08-19 | 2001-09-27 | Джапан Тобакко Инк. | Derivatives of propionic acid and pharmaceutical composition based on thereof |
| CN1781915A (en) * | 1998-03-30 | 2006-06-07 | 日本烟草产业株式会社 | Process for preparing oxazolylethanol derivatives |
| ES2226377T3 (en) * | 1998-05-11 | 2005-03-16 | Takeda Chemical Industries, Ltd. | DERIVATIVES OF OXIIMINO-ALCALINO ACID WITH HYPOGLUCEMIC AND HYPOLIPIDEMIC ACTIVITY. |
| GB9817118D0 (en) * | 1998-08-07 | 1998-10-07 | Glaxo Group Ltd | Pharmaceutical compounds |
| PL351898A1 (en) * | 1999-04-06 | 2003-06-30 | Sankyo Co | O-substituted derivatives of carboxylic acids |
| TWI302149B (en) | 1999-09-22 | 2008-10-21 | Bristol Myers Squibb Co | Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method |
| DE10031657A1 (en) | 2000-06-29 | 2002-01-24 | Siemens Ag | High-frequency component |
| DK1313716T3 (en) * | 2000-08-23 | 2007-08-27 | Lilly Co Eli | Oxazolyl-arylpropionic acid derivatives and their use as PPAR agonists |
| RU2278859C2 (en) * | 2001-05-15 | 2006-06-27 | Ф.Хоффманн-Ля Рош Аг | Oxazole derivatives substituted with carboxylic acids as ppar-alpha and ppar-gamma activators in diabetes treatment |
| AR041481A1 (en) * | 2002-10-07 | 2005-05-18 | Hoffmann La Roche | ARILPROPIONIC-OXAZOL ACID DERIVATIVES AND ITS USE AS PPAR AGONISTS |
-
2003
- 2003-10-03 AR ARP030103607A patent/AR041481A1/en active IP Right Grant
- 2003-10-03 TW TW092127469A patent/TWI343915B/en not_active IP Right Cessation
- 2003-10-06 GT GT200300218A patent/GT200300218A/en unknown
- 2003-10-06 PT PT03757914T patent/PT1551814E/en unknown
- 2003-10-06 PL PL376363A patent/PL208743B1/en not_active IP Right Cessation
- 2003-10-06 BR BR0315114-0A patent/BR0315114A/en active Search and Examination
- 2003-10-06 EP EP03757914A patent/EP1551814B1/en not_active Expired - Lifetime
- 2003-10-06 PE PE2003001007A patent/PE20040591A1/en not_active Application Discontinuation
- 2003-10-06 RU RU2005114373/04A patent/RU2303593C2/en not_active IP Right Cessation
- 2003-10-06 KR KR1020057005924A patent/KR100623819B1/en not_active Expired - Fee Related
- 2003-10-06 DK DK03757914T patent/DK1551814T3/en active
- 2003-10-06 MX MXPA05003392A patent/MXPA05003392A/en active IP Right Grant
- 2003-10-06 PA PA20038584501A patent/PA8584501A1/en unknown
- 2003-10-06 JP JP2004540787A patent/JP4414886B2/en not_active Expired - Fee Related
- 2003-10-06 AU AU2003273949A patent/AU2003273949B2/en not_active Ceased
- 2003-10-06 WO PCT/EP2003/011030 patent/WO2004031162A1/en not_active Ceased
- 2003-10-06 ES ES03757914T patent/ES2311110T3/en not_active Expired - Lifetime
- 2003-10-06 NZ NZ538465A patent/NZ538465A/en not_active IP Right Cessation
- 2003-10-06 SI SI200331311T patent/SI1551814T1/en unknown
- 2003-10-06 CN CNB2003801010744A patent/CN100415727C/en not_active Expired - Fee Related
- 2003-10-06 HR HR20050308A patent/HRP20050308A2/en not_active Application Discontinuation
- 2003-10-06 CA CA2499721A patent/CA2499721C/en not_active Expired - Fee Related
- 2003-10-06 UY UY28006A patent/UY28006A1/en not_active Application Discontinuation
- 2003-10-06 DE DE60322408T patent/DE60322408D1/en not_active Expired - Lifetime
- 2003-10-06 AT AT03757914T patent/ATE402153T1/en active
- 2003-10-06 US US10/679,604 patent/US6969725B2/en not_active Expired - Fee Related
- 2003-10-06 MY MYPI20033798A patent/MY143576A/en unknown
-
2005
- 2005-02-24 NO NO20051011A patent/NO330171B1/en not_active IP Right Cessation
- 2005-03-03 IL IL167250A patent/IL167250A/en not_active IP Right Cessation
- 2005-04-01 ZA ZA200502664A patent/ZA200502664B/en unknown
- 2005-04-04 CO CO05029209A patent/CO5540385A2/en not_active Application Discontinuation
- 2005-07-18 US US11/183,360 patent/US7348349B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20055680L (en) | Hexahydropyridoisoquinolines as DPP-IV inhibitors | |
| NO20055887L (en) | Pyrido'2,1-A-isoquinolide derivatives as DPP-IV inhibitors | |
| CA2368347A1 (en) | Glucokinase activators | |
| NO20072389L (en) | Substituted benzoquinoline derivatives | |
| CA2474578A1 (en) | Novel pyridin- and pyrimidin-derivatives | |
| NO20044501L (en) | [1,4] diazenino [6,7,1-IJ] quinoline derivatives such as antipsychotics and antidepressants | |
| MXPA04009784A (en) | Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors. | |
| CA2445145A1 (en) | Carboxylic acid substituted oxazole derivatives for use as ppar-alpha and -gamma activators in the treatment of diabetes | |
| HUP9600448A2 (en) | Naphthyl compounds, pharmaceutical compositions containing them, process for producing them, their intermediates and their use | |
| TWI265163B (en) | Novel pyrido[2,1-a]isoquinoline derivatives | |
| AU2003258621A1 (en) | Novel purine derivatives, production and use thereof as medicaments | |
| NO20052914L (en) | Therapeutic compounds | |
| NO944911L (en) | Non-peptide takykininreseptorantagonister | |
| AU4396899A (en) | Remedies for diabetes | |
| NO20073830L (en) | Medications for the treatment or prevention of fibrotic diseases | |
| IL159412A0 (en) | A synergistic pharmaceutical combination for the prevention or treatment of diabetes | |
| NO20051011L (en) | Chiral oxazole-arylpropionic acid derivatives and their use as PPAR agonists | |
| NO20051901L (en) | New antimycobacterial compositions and pyrrole derivatives such as antimycobacterial compositions | |
| AU3623399A (en) | Use of benzofuroxan derivatives in treating angina pectoris | |
| IL166103A0 (en) | Pyrrolidine derivatives and their use | |
| WO2003018010A1 (en) | Preventive and/or remedial agent for disease attributable to arteriosclerotic activity | |
| NO20054168L (en) | Substituted 3- (benzoylureido) thiophene derivatives, process for preparation and use thereof | |
| WO1998056759A3 (en) | Novel pentaerythrite derivatives, the production and use thereof and intermediate products for the synthesis of the same | |
| PL377462A1 (en) | Oligosaccharide derivative | |
| DE69818060D1 (en) | POLYHYDROXYALKYLPYRAZINE DERIVATIVES, THE PRODUCTION THEREOF, THE MEDICINAL PRODUCTS CONTAINING THEM |